viewZelira Therapeutics Ltd

Zelda Therapeutics aims to launch medicinal cannabis HOPE® range early 2020

Zelda recently detailed its intention to merge with Ilera Therapeutics to create a leading medicinal cannabis company rebranded Zelira Therapeutics.

Zelda Therapeutics Ltd - Zelda Therapeutics aims to launch medicinal cannabis HOPE® range early 2020
The merger is pending as it requires shareholder approval

Zelda Therapeutics Ltd (ASX:ZLD) will acquire the HOPE® range of medicinal cannabis products as part of its proposed merger with Ilera Therapeutics.

The products were formulated for symptoms associated with autism spectrum disorder.

The HOPE® (HOPE 1 & 2) products were launched in Pennsylvania in May 2019 with the support of leading advocacy group HOPE Grows for Autism.

Notably, feedback from patients has consistently shown success with and acceptance of HOPE® and since its launch it has become a top-selling product in Ilera’s portfolio.

Plan is to launch early 2020

A key priority for Zelira post-merger will be to launch HOPE® into global markets from early 2020, with the aim of generating revenues in the first half of the year.

In the US, Zelira’s strategy will be to license HOPE® into multiple states using a virtual distribution model.

In ex-US markets, Zelira will leverage its existing network of suppliers and distributors to market HOPE® in different countries.

These include Germany, Australia and the UK, which together represent the fastest growing global markets.

Growing focus on autism

Autism is already a focus of Zelda’s making the HOPE® products a strategic fit.

Zelda has previously undertaken a pilot clinical study in Chile to assess the efficacy of medicinal cannabis formulations in children diagnosed with autism.

More recently, Zelda has funded one of the world’s largest observational studies to assess the real-world use and impact of medicinal cannabis in children with autism spectrum disorder.

Both studies have provided evidence that treatment with medicinal cannabis can improve behaviours associated with autism and data is being used to design an interventional trial.

Quick facts: Zelira Therapeutics Ltd

Price: 0.066 AUD

Market: ASX
Market Cap: $75.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...


Zelira Therapeutics with Proactive at ASX Small and Mid-Cap Conference

Zelira Therapeutics Ltd (ASX:ZLD) managing director Richard Hopkins speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.  The medicinal cannabis company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing...

1 week, 2 days ago

2 min read